Bivalirudin
Also known as: Angiomax, Angiox
Key Facts: Bivalirudin
- Category
- Hormonal
- FDA Status
- FDA Approved
- Clinical Status
- FDA Approved - PCI anticoagulation
- Administration
- IV bolus and infusion
- Typical Dose
- Limited community data available
- Frequency
- See research protocols
- Evidence Level
- FDA Approved
- Duration
- Duration of procedure
What to Expect
A synthetic direct thrombin inhibitor derived from hirudin. Used as an anticoagulant during PCI procedures.
Mechanism of Action
Bivalirudin directly inhibits thrombin by binding to both its active site and exosite 1. Unlike heparin, it inhibits both free and clot-bound thrombin. Predictable anticoagulation without need for antithrombin.
Research Summary
HORIZONS-AMI and other trials established efficacy in PCI. Lower bleeding risk than heparin plus GP IIb/IIIa inhibitors in many settings. Short half-life allows rapid offset.
Dosing Information
Typical Dosingⓘ
Community experience
Limited community data available
See research dosing
See research protocols
Research Dosingⓘ
Scientific studies
Procedural use
Doses from Studies
0.75 mg/kg IV bolus
1.75 mg/kg/h infusion during procedure
Duration
Duration of procedure
Administration
IV bolus and infusion
Timing & Administration
Best Time to Take
Morning or as directed
Follow recommended protocol
Food Recommendation
With or without food
Why This Timing?
Timing may vary based on individual response and goals. Consistency is generally more important than specific timing.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Bleeding (28%)
- ●Headache
- ●Thrombocytopenia
- ●Hypotension
- ●Acute stent thrombosis (higher than heparin)
- ●Allergic reactions
- ●FDA approved (Angiomax)
References
Related Peptides
Peptides commonly compared with Bivalirudin or used in similar applications.
Oxytocin
FDAA naturally occurring peptide hormone crucial for social bonding, childbirth, and lactation. Being studied for autism, anxiety, and social disorders.
HormonalGonadorelin
FDAA synthetic version of gonadotropin-releasing hormone. Used diagnostically and therapeutically for various reproductive and hormonal conditions.
HormonalLeuprolide
FDAA GnRH agonist that suppresses testosterone and estrogen production. FDA approved for prostate cancer, endometriosis, uterine fibroids, and precocious puberty.
HormonalDesmopressin
FDAA synthetic analog of vasopressin (ADH) used for diabetes insipidus, bedwetting, and bleeding disorders. Does not cause vasoconstriction like natural vasopressin.
HormonalOctreotide
FDAA synthetic somatostatin analog that inhibits multiple hormones. Used for acromegaly, carcinoid tumors, and various GI conditions.
HormonalLanreotide
FDAA long-acting somatostatin analog similar to octreotide. FDA approved for acromegaly and gastroenteropancreatic neuroendocrine tumors.
HormonalWant updates on Bivalirudin research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.